Background: Psoriasis known as a chronic inflammatory skin disease is accompanied by metabolic disorders such as obesity, diabetes, and dyslipidemia. Vaspin (a serine protease inhibitor derived from visceral adipose tissue) is a newly identified adipokine and a link between inflammation and obesity has been reported. We aimed to determine whether vaspin gene polymorphism is associated with the development and/or clinical features of psoriasis vulgaris. Methods: Our study group consisted of 96 psoriasis vulgaris patients and 100 matched controls. Vaspin rs2236242 gene was genotyped using PCR. Results: The vaspin genotypes showed a meaningful difference between psoriasis and control groups (p = 0.02). The frequency of the vaspin rs2236242 TT genotype was lower in psoriasis patients than in control participants (p < 0.05). The TA genotype was associated with a 2.38-fold increased risk of psoriasis compared to the TT genotype (p = 0.007, odds ratio: 2.38; 95% confidence interval: 1.25–4.55), but not the AA genotype. All subjects were the Turkish population, the study in other populations is needed and the sample size was small in number. Conclusion: Our study demonstrated that vaspin rs2236242 polymorphism is related to psoriasis in the Turkish population. Polymorphisms of the vaspin gene might serve as diagnostic biomarkers of psoriasis.

1.
Santus
P
,
Rizzi
M
,
Radovanovic
D
,
Airoldi
A
,
Cristiano
A
,
Conic
R
, et al
Psoriasis and respiratory comorbidities: the added value of fraction of exhaled nitric oxide as a new method to detect, evaluate, and monitor psoriatic systemic involvement and therapeutic efficacy
.
Biomed Res Int
.
2018
;
23
:
3140682
. .
2.
Neimann
AL
,
Shin
DB
,
Wang
X
,
Margolis
DJ
,
Troxel
AB
,
Gelfand
JM
.
Prevalence of cardiovascular risk factors in patients with psoriasis
.
J Am Acad Dermatol
.
2006
;
55
(
5
):
829
35
. .
3.
Chiricozzi
A
,
Gisondi
P
,
Girolomoni
G
.
The pharmacological management of patients with comorbid psoriasis and obesity
.
Expert Opin Pharmacother
.
2019
;
20
(
7
):
863
72
. .
4.
Saalbach
A
,
Tremel
J
,
Herbert
D
,
Schwede
K
,
Wandel
E
,
Schirmer
C
, et al
Anti-inflammatory action of keratinocyte-derived vaspin: relevance for the pathogenesis of psoriasis
.
Am J Pathol
.
2016
;
186
(
3
):
639
51
. .
5.
Dimova
R
,
Tankova
T
.
The role of vaspin in the development of metabolic and glucose tolerance disorders and atherosclerosis
.
Biomed Res Int
.
2015
;
2015
:
823481
. .
6.
Saalbach
A
,
Vester
K
,
Rall
K
,
Tremel
J
,
Anderegg
U
,
Beck-Sickinger
AG
, et al
Vaspin: a link of obesity and psoriasis?
Exp Dermatol
.
2012
;
21
(
4
):
309
12
. .
7.
Li
J
,
Li
Q
,
Zhu
YC
,
Wang
YK
,
Gao
CP
,
Li
XY
, et al
Association of vaspin rs2236242 gene variants with type 2 diabetes and obesity in a Chinese population: a prospective, single-center study
.
J Cell Physiol
.
2019 20
. .
8.
Kempf
K
,
Rose
B
,
Illig
T
,
Rathmann
W
,
Strassburger
K
,
Thorand
B
, et al
Vaspin (SERPINA12) genotypes and risk of type 2 diabetes: results from the MONICA/KORA studies
.
Exp Clin Endocrinol Diabetes
.
2010
;
118
(
3
):
184
9
. .
9.
Mehanna
ET
,
Mesbah
NM
,
Ghattas
MH
,
Saleh
SM
,
Abo-Elmatty
DM
.
Association of chemerin Rs17173608 and vaspin Rs2236242 gene polymorphisms with metabolic syndrome in Egyptian women
.
Endocr Res
.
2016
;
41
(
1
):
43
8
. .
10.
Hashemi
M
,
Rezaei
H
,
Eskandari-Nasab
E
,
Kaykhaei
MA
,
Zakeri
Z
,
Taheri
M
.
Association between chemerin rs17173608 and vaspin rs2236242 gene polymorphisms and the metabolic syndrome, a preliminary report
.
Gene
.
2012
;
510
(
2
):
113
7
. .
11.
Louden
BA
,
Pearce
DJ
,
Lang
W
,
Feldman
SR
.
A Simplified Psoriasis Area Severity Index (SPASI) for rating psoriasis severity in clinic patients
.
Dermatol Online J
.
2004
;
10
(
2
):
7
.
12.
Ponez
M
,
Solowiejczyk
D
,
Harpel
B
,
Mory
Y
,
Schwartz
E
,
Surrey
S
, et al
Construction of human gene libraries from small amounts of peripheral blood
.
Hemoglobin
.
1982
;
6
:
27e36
. .
13.
Kohan
L
,
Zarei
A
,
Fallahi
S
,
Tabiee
O
.
Association between vaspin rs2236242 gene polymorphism and polycystic ovary syndrome risk
.
Gene
.
2014
;
539
:
209
12
. .
14.
Coban
M
,
Tasli
L
,
Turgut
S
,
Özkan
S
,
Tunç Ata
M
,
Akın
F
.
Association of adipokines, insulin resistance, hypertension and dyslipidemia in patients with psoriasis vulgaris
.
Ann Dermatol
.
2016
;
28
(
1
):
74
9
. .
15.
de Oliveira Leal
V
,
Mafra
D
.
Adipokines in obesity
.
Clinica Chimica Acta
.
2013
;
419
(
18
):
87
94
. .
16.
Gerdes
S
,
Rostami-Yazdi
M
,
Mrowietz
U
.
Adipokines and psoriasis
.
Exp Dermatol
.
2011
;
20
(
2
):
81
7
. .
17.
Toulza
E
,
Mattiuzzo
NR
,
Galliano
MF
,
Jonca
N
,
Dossat
C
,
Jacob
D
, et al
Large-scale identification of human genes implicated in epidermal barrier function
.
Genome Biol
.
2007
;
8
(
6
):
R107
. .
18.
Russell
CB
,
Rand
H
,
Bigler
J
,
Kerkof
K
,
Timour
M
,
Bautista
E
, et al
Gene expression profiles normalized in psoriatic skin by treatment with brodalumab, a human anti-IL-17 receptor monoclonal antibody
.
J Immunol
.
2014
;
192
(
8
):
3828
. .
19.
Suarez-Farinas
M
,
Lowes
MA
,
Zaba
LC
,
Krueger
JG
.
Evaluation of the psoriasis transcriptome across different studies by gene set enrichment analysis (GSEA)
.
PLoS One
.
2010
;
5
:
e10247
. .
20.
Yao
Y
,
Richman
L
,
Morehouse
C
,
de los Reyes
M
,
Higgs
BW
,
Boutrin
A
, et al
Type I interferon: potential therapeutic target for psoriasis?
PLoS One
.
2008
;
3
(
7
):
e2737
. .
21.
Ataseven
A
,
Kesli
R
.
Novel inflammatory markers in psoriasis vulgaris: vaspin, vascular adhesion protein-1 (VAP-1), and YKL-40, G. Ital. Dermatol
.
Venereol
.
2016
;
151
:
244
50
.
22.
Abdel-Ghany
SM
,
Sayed
AA
,
El-Deek
SEM
,
ElBadre
HM
,
Dahpy
MA
,
Saleh
MA
, et al
Obesity risk prediction among women of Upper Egypt: the impact of serum vaspin and vaspin rs2236242 gene polymorphism
.
Gene
.
2017
;
626
:
140
8
. .
23.
Henseler
T
,
Christophers
E
.
Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris
.
J Am Acad Dermatol
.
1985
;
13
(
3
):
450
6
. .
24.
Nomani
H
,
Khanmohamadian
H
,
Vaisi-Raygani
A
,
Shakiba
E
,
Tanhapour
M
,
Rahimi
Z
.
Chemerin rs17173608 and vaspin rs2236242 gene variants on the risk of end stage renal disease (ESRD) and correlation with plasma malondialdehyde (MDA) level
.
Ren Fail
.
2018
;
40
(
1
):
350
6
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.